KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Gains from Investment Securities (2016 - 2025)

Neogenomics filings provide 16 years of Gains from Investment Securities readings, the most recent being $5.9 million for Q4 2025.

  • On a quarterly basis, Gains from Investment Securities rose 1892.95% to $5.9 million in Q4 2025 year-over-year; TTM through Mar 2026 was $6.4 million, a 1111.55% increase, with the full-year FY2025 number at $6.4 million, up 936.79% from a year prior.
  • Gains from Investment Securities hit $5.9 million in Q4 2025 for Neogenomics, up from $458000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $7.3 million in Q4 2023 to a low of -$49000.0 in Q1 2021.
  • Median Gains from Investment Securities over the past 5 years was $129000.0 (2022), compared with a mean of $990800.0.
  • Biggest five-year swings in Gains from Investment Securities: tumbled 2550.0% in 2021 and later skyrocketed 29280.0% in 2023.
  • Neogenomics' Gains from Investment Securities stood at $35000.0 in 2021, then fell by 28.57% to $25000.0 in 2022, then skyrocketed by 29280.0% to $7.3 million in 2023, then crashed by 95.94% to $298000.0 in 2024, then surged by 1892.95% to $5.9 million in 2025.
  • The last three reported values for Gains from Investment Securities were $5.9 million (Q4 2025), $458000.0 (Q2 2025), and $298000.0 (Q4 2024) per Business Quant data.